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This is a phase 2 dose escalation trial of carfilzomib in combination with thalidomide and 
dexamethasone  for induction and consolidation in transplant-eligible patients with newly 
diagnosed multiple myeloma. The results of 4 dose levels are reported. Induction therapy 
consisted of 4 cycles of carfilzomib 20/27 mg/m2 (n=50), 20/36 mg/m2 (n=20), 20/45 mg/m2 
(n=21) and 20/56 mg/m2 (n=20) on days 1, 2, 8, 9, 15, 16 of a 28-day cycle; thalidomide 200 mg 
on day 1 through 28 and dexamethasone 40 mg weekly. Induction therapy was followed by high 
dose melphalan and autologous stem cell transplantation and consolidation therapy with 4 
cycles of carfilzomib, thalidomide and dexamethasone in the same schedule except a lower 
dose of thalidomide (50 mg).  
Very good partial response rate  or better and complete response  rate or better after induction 
therapy were 65% and 18% respectively, increasing to 86% and 63% respectively after 
consolidation therapy. In all cohorts combined, after a median follow-up of 58.7 months, median 
progression-free survival was 58 months (95% CI 45-67 months). Median overall survival was 
83 months (95% CI 83 months-not reached). Grade 3/4 adverse events consisted mainly of 
infections, respiratory disorders, skin and vascular disorders in 11%, 8%, 9%, and 9% 
respectively. Only in 1 patient grade 3 polyneuropathy was reported. Cardiac events were 
limited, grade 3/4 in 5% of patients. Carfilzomib, thalidomide and dexamethasone as induction 
and consolidation treatment after  high dose melphalan and autologous stem cell transplantation 
is highly efficacious and safe in transplant-eligible patients with newly diagnosed multiple 





Survival rates in patients with multiple myeloma (MM) have significantly improved during the last 
decades. However, eventually the majority of patients progress and the need for new 
therapeutic approaches remains. In transplant-eligible patients with newly diagnosed multiple 
myeloma (NDMM), depth of response before and after high-dose melphalan/autologous stem 
cell transplantation (HDM/ASCT) is associated with improvement in progression-free survival 
(PFS) and overall survival (OS).(1-5) Therefore, it is important to select the appropriate 
induction and consolidation therapy in order to achieve a maximum response after ASCT and to 
maintain or even increase this response during consolidation therapy and thereafter.  
Standard induction treatment consists of triple therapy including a proteasome inhibitor, and/or 
an immunomodulatory drug and dexamethasone. The combination of bortezomib, thalidomide 
and dexamethasone (VTD) has been extensively investigated in transplant-eligible patients with 
NDMM.(6-8) However, treatment with bortezomib is associated with higher rates of 
polyneuropathy (PN) and consequently discontinuation of treatment.(7, 8) It is important to use 
a regimen that is highly effective and safe in patients with NDMM. This could improve treatment 
adherence and subsequently outcome after induction and consolidation therapy. 
Carfilzomib is a selective proteasome inhibitor with irreversible binding to the constitutive 
proteasome and immunoproteasome. It is approved in the United States and in Europe as a 
single-agent for the treatment of patients with relapsed and/or refractory MM (RRMM). 
Carfilzomib is approved at a dose of 27 mg/m2 in combination with lenalidomide and 
dexamethasone in RRMM based on the data from the ASPIRE trial showing a superior PFS of 
median 26.3 months vs 17.4 months when patients were treated with 
lenalidomide/dexamethasone.(9) Carfilzomib is also approved at a dose of 56 mg/m2 in 
combination with dexamethasone, based on data from the ENDEAVOR trial showing a superior 




Previous trials showed that the incidence of PN with carfilzomib is lower compared to 
bortezomib.(9-11)  
Carfilzomib is not yet approved for treatment in NDMM in Europe. Recent trials in patients with 
NDMM, using different treatment regimens, showed high response rates.(12-15) A phase 1/2 
trial of patients with NDMM treated with carfilzomib at a maximum dose of 36 mg/m2 combined 
with lenalidomide and low-dose dexamethasone showed a very good partial response (VGPR) 
rate of 81%. PFS at 24 months was 92%.(12) 
We have previously initiated a Phase 2 dose-escalation trial of carfilzomib combined with 
thalidomide and dexamethasone. The combination of a proteasome inhibitor and an 
immunomodulating agent has a proven synergystic effect.(6) Moreover, thalidomide is an 
effective and affordable drug available in many countries. 
In NDMM no consensus exists about the optimum dose level of Carfilzomib, implicating the 
need for dose finding trials. Goal of this trial was to investigate the efficacy of this combination at 
various dose levels of carfilzomib  in NDMM. Results of the first three cohorts of this Carthadex 
trial have been published in 2015.(11) Overall response rate (ORR) after induction therapy was 
90% with a VGPR rate of 68%. PFS at 36 months was 72%. The combination of carfilzomib, 
thalidomide and dexamethasone (KTd) was well tolerated.(11). Four different dose levels were 
included in this trial based on the hypothesis that a higher dose level  induces a higher response 
rate.(12, 16) We report herein the results of our dose escalation cohorts with long follow-up. 
This is the first study using KTd for both induction and consolidation therapy and comparing 






Transplant-eligible patients with NDMM, aged 18 to 65 years, could be enrolled. Patients were 
required to have a World Health Organization (WHO) performance status of 0 to 3 (WHO 3 was 
allowed only when caused by MM and not by co-morbid conditions).  
Patients were ineligible if they had grade 3/4 polyneuropathy (PN) or grade 2 painful PN, severe 
cardiac dysfunction (New York Heart Association class II to IV), known intolerance of 
thalidomide, systemic amyloid light-chain amyloidosis, non-secretory MM, Waldenström 
macroglobulinemia or IgM MM, creatinine clearance < 15 mL/min, absolute neutrophil count < 
1.0 x 109/L, platelets < 75 x 109/L, hemoglobin < 4.9 mmol/L, active malignancy during the past 
5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma. 
This independent investigator-initiated multi-institutional study was conducted in accordance 
with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for 
Good Clinical Practice, and the European Clinical Trial Directive as implemented in Dutch law. 
The protocol was approved by institutional review boards and ethics committees. All patients 
signed an informed consent. 
Study design and treatment 
This single-arm, open-label, phase 2 trial was conducted at 8 hematology centers. Patients 
were treated with 4 cycles KTd of a 28-day cycle for induction therapy. Carfilzomib was 
administered in a 30 minutes infusion. The dose in the first dosing cohort was 20 mg/m2 on days 
1 and 2 and was escalated to a dose of 27 mg/m2 on days 8, 9, 15 and 16 of cycle 1 and on 
days 1, 2, 8, 9, 15 and 16 of cycles 2 to 4. Thalidomide 200 mg was given orally on days 1 
through 28 and dexamethasone 40 mg was given orally on days 1, 8, 15 and 22. Induction 
therapy was followed by stem cell harvest after Cyclophosphamide priming (2 to 4 mg/m2 IV) 




Melphalan (HDM, 200mg/m2) and ASCT followed by consolidation treatment with 4 cycles of 
KTd in the same schedule and dose as induction treatment except that the dose of thalidomide 
was 50 mg instead of 200 mg. The dose of carfilzomib was escalated to 20/36 mg/m2, 20/45 
mg/m2 and 20/56 mg/m2 in cohort 2, 3 and 4 respectively. During the study protocol patients 
were required to maintain adequate hydration. In addition, patients were treated prophylactically 
with antibiotics (ciprofloxacin or another fluoroquinolone) and with antiviral medication (acyclovir 
or a similar anti varicella agent). All patients received antithrombotic prophylaxis with aspirin in 
case of low thrombotic risk or with low-molecular-weight heparin in patients with pre-existing 
thrombotic risk factors.(17) 
The primary endpoint of the study was response after induction therapy and overall response, 
specifically complete response (CR) and VGPR. Secondary endpoints were efficacy and safety, 
maximum tolerated dose (MTD), dose limiting toxicities (DLT), PFS and overall survival (OS). 
PFS was defined as time from registration to progression or death, whichever came first. OS 
was calculated from registration to death from any cause; patients still alive at last contact were 
censored. 
This study was registered at http://www.trialregister.nl as #NTR2422. 
Assessments 
Treatment responses and disease progression were assessed by study investigators and were 
classified according to International Myeloma Working Group (IMWG) Uniform Response 
Criteria, with categories for CR, VGPR, and partial response (PR).(18) Toxicity was assessed 
according to the National Cancer Institute Common Terminology Criteria of Adverse Events 
version 4.0.(19) Bone marrow analysis was performed at diagnosis to quantify myeloma cell 
involvement. Molecular, cytogenetic and fluorescence in situ hybridization studies were 
performed on these samples. CD138+ purified MM cells were used to determine the presence 




del(17p), 1p/q abnormalities, numerical abnormalities of chromosome 9 or 11, and complex 
cytogenetic abnormalities.(11)  
Statistical analysis 
This study was designed to investigate whether induction treatment with KTd warrants further 
investigation in future trials. The intention-to-treat principle was used for all analyses, restricted 
to eligible patients. A CR + VGPR rate lower than 25% after induction treatment, was 
considered too low to warrant further investigation in future trials, however if the CR + VGPR 
rate was higher than 45% therapeutic activity was considered sufficiently high to support further 
investigation. To reject the null hypothesis in favor of the alternative hypothesis with power 1 - β 
= 0.80 (2-sided significance level α = 0.05), a minimum of 41 patients should be included. A 
95% confidence interval (CI) was constructed around the CR + VGPR rate after induction 
treatment and the null hypothesis was rejected if the lower boundary was larger than 25%. 
Predefined subgroup analyses were performed to investigate the effect of risk status, using 
cytogenetic/fluorescence in situ hybridization criteria, ISS stage and R-ISS stage, on response 
and survival. In this trial patients were considered to be high-risk if they had t(4;14) and/or 
del(17p) and/or add(1q) and/or ISS stage III.   
Continuous and categorical data were summarized with descriptive statistics. Survival end 
points were estimated using the Kaplan-Meier method, and 95% CI were constructed. The log- 
rank was used to evaluate differences in PFS and OS between subgroups. Statistical analysis 







Patients and treatment 
One hundred and eleven patients were enrolled between September 16, 2010 and December 
30, 2013. The analysis was based on data available as of February 27, 2018 with a median 
follow-up of 58.7 months (range 25.1-88.0 months). Four different dose levels were investigated 
(27mg/m2 n=50, 36 mg/m2 n=20, 45 mg/m2 n=21 and 56 mg/m2 n=20). Baseline demographics 
and disease characteristics are shown in table 1. Median age was 58 years with a range of 29 
to 66 years and the male/female distribution 61/39%. Nine percent of patients had an R-ISS 
stage 3 and in 9% of patients R-ISS stage was unknown mainly due to missing cytogenetics. A 
total of 39% of patients were classified as high-risk based on cytogenetics and ISS stage, 41% 
of patients were classified as standard risk. In 20% of patients risk status was unknown, mainly 
due to missing cytogenetics. Seven patients had a history of grade 1/2 PN and two patients a 
grade 3 PN at diagnosis, whereas in 9 patients baseline assessment of PN was missing at 
enrollment. A total of 5% of patients had renal insufficiency with a creatinine ≥ 177 µmol/L at 
diagnosis. 
All 111 patients started induction therapy with KTd (figure 1). Six patients discontinued 
treatment because of the following adverse events (AEs): grade 3 rash (carfilzomib 27 mg/m2), 
grade 2 fever with sepsis (carfilzomib 27 mg/m2), grade 1 hyponatremia (carfilzomib 27 mg/m2), 
grade 2 exanthema (carfilzomib 27 mg/m2), grade 3 congestive heart failure (carfilzomib 27 
mg/m2), grade 3 pneumonitis (carfilzomib 36 mg/m2), grade 3 drug reaction with eosinophilia 
and systemic symptoms (Dress syndrome) (carfilzomib 56 mg/m2). One patient appeared not 
eligible for further treatment and two patients discontinued treatment due to progressive 
disease. 102/111 patients (92%) continued treatment with high dose cyclophosphamide and 
stem cell collection. Stem cell collection was successful in 100 of 102 patients with a median 




(200 mg/m2) and ASCT. Four patients were not eligible for HDM, one because of insufficient 
CD34+ yield and three because of progression of disease after stem cell collection. After 
treatment with HDM and ASCT 94 patients (85%) initiated consolidation therapy. Four patients 
were not eligible for consolidation treatment because of progression of disease (n=1), a delayed 
hematologic recovery after ASCT (n=1), non-related disease (n=1) and uncontrolled pain after 
ASCT (n=1). Nine patients discontinued consolidation treatment because of progressive 
disease (n=2), thrombotic thrombocytopenic purpura (TTP)  (n=1), a TTP like syndrome (n=1), 
overall worsening of condition (n=1), grade 3 fatigue (n=1), refusal of further treatment (n=2) 
and persisting PNP (n=1). A total of 83 patients (75%) completed all 4 consolidation cycles.  
Efficacy 
Table 2 shows response to induction, HDM/ASCT and consolidation therapy. Response 
according to risk group and R-ISS is shown in table 3. Overall response after induction therapy 
in all 111 patients was 93% with a CR rate of 18%. The ≥ VGPR rate after induction therapy 
was 65% (95% CI 55% to 74%) leading to rejection of the null hypothesis, as the 95% CI is 
above 25%. The ≥ VGPR rate increased to 77% after HDM/ASCT and to 86% after 
consolidation therapy. ORR increased to 94% after consolidation therapy. CR rate after 
induction therapy between the four different dose levels was comparable and increased after 
consolidation therapy. In the three highest dose levels CR rate after consolidation therapy was 
higher in comparison to the lowest dose level (75%, 67% and 65% vs. 56%, respectively, 
however this was not statistically significant (test for trend, p=0.39; chi-square test 27 mg/m2 vs 
36-56 mg/m2, p=0.16)). Response after consolidation treatment between standard risk patients 
and high-risk patients (defined by ISS stage and cytogenetics) was similar with CR rates of 67% 
vs 58%. Response after consolidation therapy according to R-ISS stage (I,II and III) was 
comparable with CR rates of 73%, 57% and 60% respectively. 




associated with PFS. Median PFS in high-risk patients was worse compared to standard risk 
patients (42 vs 60 months, p=0.006), while a higher R-ISS stage was also associated with a 
worse PFS (p=0.04) (figure 2).  
Median OS was 83 months and 5-year OS was 76% (95% CI 66% to 83%) as shown in figure 3. 
Dose level and risk status were not associated with OS. 
 
Safety 
Any grade hematological toxicity occurred in 15% of patients. Grade 3/4 hematological toxicity 
occurred in 10% of patients. In dose level 27 mg/m2, 36 mg/m2, 45 mg/m2 and 56mg/m2 grade 
3/4 hematological toxicity occurred in 12%, 10%, 10% and 10% respectively. Main grade 3/4 
non-hematological toxicity consisted of infections, respiratory disorders, skin and vascular 
disorders in 11%, 8%, 9%, and 9% respectively. There was a gradual increase in grade 3/4 
infections from lower to higher doses of carfilzomib; 0%, 5%, 10% and 15% respectively, and 
consisted mainly of  pneumonia (supplementary table 1).  
Table 4 summarizes cardiac AEs. Any grade cardiac AEs were reported in 12% of patients after 
induction therapy (14% in carfilzomib 27mg/m2, 15% in carfilzomib 36 mg/m2, 19% in carfilzomib 
45 mg/m2 and 5% in carfilzomib 56mg/m2.) These cardiac events consisted mainly of grade 1/2 
toxicity (11 out of 15 events). Five (5%) grade 3 cardiac AEs were reported, three in dose level 
27 mg/m2, one in dose level 45 mg/ m2 and one in dose level 56 mg/m2. 
Any grade cardiac AEs increased to 18% after consolidation therapy with no reports of grade 4 
AEs in all four dose levels, (18% in carfilzomib 27mg/m2, 15% in carfilzomib 36 mg/m2, 19% in 
carfilzomib 45 mg/m2 and 15% in carfilzomib 56mg/m2.) These cardiac events consisted mainly 
of grade 1/2 toxicity (14 out of 19 events). Five (5%) grade 3 cardiac AEs were reported. 
Nine patients (8%) developed hypertension during treatment (carfilzomib 27 mg/m2 n=3, 




them had grade 3 toxicity. Five (5%) patients needed antihypertensive treatment.  
Seven patients (6%) had preexisting PN grade 1/2 and two patients (2%) had preexisting grade 
3 PN. During induction and consolidation therapy 52 patients (47%) developed PN. Grade ≥ 2 
PN events occurred in 23 patients (20%) independent from carfilzomib dose and was clinically 
manageable (carfilzomib 27 mg/m2 n=11, carfilzomib 36 mg/m2 n=3, carfilzomib 45 mg/m2 n=6, 
carfilzomib 56 mg/m2 n=3). Only one patient (1%) reported grade 3 PN (carfilzomib 27mg/m2).  
At least one Serious AE (SAE) was reported in 43% of patients. In cohort 1 an SAE was 
reported in 21 (42%) patients, in cohort 2 in 8 (40%) patients, in cohort 3 in 7 (33%) patients and 
in cohort 4 in 12 (60%) patients.  
As shown earlier 9 patients (8%) discontinued treatment protocol due to excessive toxicity, six 
patients during induction therapy and three patients during consolidation therapy. In cohort 1, 
four (8%) patients went off protocol due to AEs, one (5%) patient in cohort 2 and four (20%) 
patients in cohort 4. Table 5 shows an analysis of treatment adherence to protocol. During 
consolidation treatment normal completion rate for carfilzomib and dexamethasone was similar 
to induction treatment whereas this was higher for thalidomide, probably due to the lower dose 
of thalidomide during consolidation treatment. A higher percentage of patients prematurely 
discontinued treatment at the highest dose level of carfilzomib (5 patients (30%)). Four patients 
(20%) had excessive toxicity and two patients (10%) requested to discontinue treatment 











Results of the first 3 dose levels of this phase 2 trial have been published before.(11) In this 
paper we discuss the results of 4 dose levels of carfilzomib. As shown before, treatment with 
KTd for induction and consolidation in transplant eligible patients with NDMM is safe, tolerable 
and effective. We included the additional cohort with the highest dose level of 56 mg/m2, based 
on the hypothesis that a higher dose level induces a higher response rate.(12, 16) Response 
after induction was high with 65% of patients reaching at least VGPR, increasing to 86% after 
consolidation therapy. CR rate after consolidation was high with 63%. Response (i.e. >CR) after 
consolidation in the higher three dose levels (20/36, 20/45, 20/56) was better than in the lowest 
dose level (20/27) however, the small sample size and the non-randomized design of the study 
preclude firm conclusions about superiority of the highest dose levels. In the ARROW trial, 478 
patients with RRMM were randomized between treatment with carfilzomib twice a week 27 
mg/m2 or once weekly 70 mg/m2. PFS was higher with once weekly 70 mg/m2 than with twice 
weekly 27 mg/m2 (11.2 months vs 7.6 months).(20) These data and our data (based on 
response) suggest that a dose of at least 36 mg/m2 twice weekly (which equals 70 mg/m2 once 
weekly), would be the preferred dose. 
An important remaining question relates to the efficacy of this regimen in high-risk patients. In 
this trial with limited numbers, the negative impact of high-risk cytogenetics was not abrogated 
by carfilzomib.(21) At the same time, overall risk status, based on cytogenetics and ISS stage, 
was not significantly associated with response. However, high-risk patients and patients with a 
higher R-ISS score had a significantly worse PFS. Median PFS and OS for all patients were 58 
months and 83 months, respectively. These data show that treatment with KTd is effective as 
frontline treatment of transplant eligible patients with NDMM. Also, this regimen had no effect on 
stem cell mobilization and collection, with the exception of 2 patients in whom stem cell 
collection failed. Several phase 2 trials have investigated treatment with carfilzomib in NDMM 




regimen. They showed a comparable ORR of 91% and a PFS at 24 months of 76%. In this 
study MTD was 20/36 mg/m2.(13) In comparison, in the Carthadex trial dose levels of 45 mg/m2  
and 56 mg/m2 were well tolerated without additional toxicity compared to dose levels 27 mg/m2  
and 36 mg/m2. The number of patients going off treatment due to excessive toxicity was low, 9 
out of 111 patients (8%). Our data show that efficacy and safety are comparable at dose levels 
36 mg/m2 and upward. Main grade 3/4 non-hematological toxicity consisted of infections, 
respiratory disorders, skin and vascular disorders. The rate of cardiac AEs was low in this trial. 
Five patients (5%) experienced grade 3 cardiac AE, including congestive heart failure, dyspnea 
and chest pain. This is comparable to other trials investigating carfilzomib in NDMM.(12-14)  
The rate of grade 3/4 cardiac toxicity is slightly higher in RRMM, most likely because patients 
are older and due to previous treatment.(9, 10) However, the limited number of patients 
preclude firm conclusions about safety regarding cardiac events between the different dose 
levels. Jakubowiak et al. performed a phase 1/2 trial of carfilzomib combined with lenalidomide 
and dexamethasone (CRd). In this trial patients not proceeding to ASCT continued treatment 
with CRd beyond 8 cycles with a median of 12 cycles. PFS at 24 months was 92%.(12) 
However, thalidomide remains a valuable and available treatment option in many countries, due 
to availability and due to low costs, and offers a great alternative to treatment with lenalidomide. 
Recently several trials have been performed in patients with NDMM,  using alternative 
schedules for induction and consolidation. The Intergroupe Francophone du Myélome (IFM) 
performed a phase 2 trial of lenalidomide combined with bortezomib and dexamethasone (RVD) 
for induction and consolidation. PFS at 3 years was 77% and CR rate was 58%. Most common 
toxicities were grade 1/2 PN in 55%.(22) In the EMN02 trial VCD for induction was followed by 
VRD for consolidation treatment. CR rate was 55% and PFS not reached at 60 months.(23) 
Although it should be taken into account that this is a cross comparison between trials, the 
Carthadex trial efficacy data are similar with median PFS of 58 months and CR rate of 63% and 




is an affordable treatment regimen. These data suggest that CTd is an effective and safe 
induction and consolidation regimen in newly diagnosed MM.  
In conclusion, the combination of carfilzomib, thalidomide and low-dose dexamethasone 
appears highly efficacious and safe in transplant-eligible patients with NDMM across all dose 
levels with manageable toxicities. Consolidation therapy after ASCT results in a major 
improvement in response. In addition, we observed that higher dose levels of carfilzomib (36 to 
56 mg/m2)  result in better response rates after consolidation therapy. Current studies in newly 
diagnosed multiple myeloma patients are performed using 36 mg/m2 twice weekly. 36 mg/m2 
twice weekly (or 70 mg/m2 once weekly) will be the preferred dose to be used in practice, which 
we would recommend based on our carthadex response data.  Results of cohort 5 in which 
patients were treated with 8 instead of 4 induction cycles will follow in the near future.  
Further randomized, prospective studies are needed to confirm these data and determine the 
position of carfilzomib in the treatment of patients with NDMM. 
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Table 1: Baseline characteristics 
Characteristic 20/27 mg/m2 20/36 mg/m2 20/45 mg/m2 20/56 mg/m2 All patients  
Patients, n  50 20 21 20 111 
Male, n (%) 34 (68) 11 (55) 16 (76) 7 (35) 68 (61)  
Age, median (range), years 58 (29-66) 58 (47-64) 56 (33-65) 58 (37-65) 58 (29-66) 
ISS stage, n (%)         
  
1 18 (36) 5 (25) 14 (67) 9 (45) 46 (41) 
2 20 (40) 7 (35) 4 (19) 7 (35) 38 (34) 
3 12 (24) 8 (40) 2 (10) 4 (20) 26 (23) 
Unknown 0 (0) 0 (0) 1 (5) 0 (0) 1 (1) 
R-ISS stage, n (%) 
1 7 (14) 3 (15) 10 (48) 6 (30) 26 (23) 
2 37 (74) 10 (50) 7 (33) 11 (55) 65 (59) 
3 2 (4) 5 (25) 0 (0) 3 (15) 10 (9) 
Unknown 4 (8) 2 (10) 4 (19) 0 (0) 10 (9) 
WHO performance status, n (%)         
  
0 24 (48) 7 (35) 11 (52) 12 (60) 54 (49) 
1 20 (40) 10 (50) 7 (33) 8 (40) 45 (41) 
2 2 (4) 1 (5) 1 (5) 0 (0) 4 (4) 
3 0 (0) 0 (0) 2 (10) 0 (0) 2 (2) 
Unknown 4 (8) 2 (10) 0 (0) 0 (0) 6 (5) 
M-protein isotype, n (%)         
  
IgA 11 (22) 5 (25) 4 (19) 4 (20) 24 (22) 
IgG 30 (60) 8 (40) 10 (48) 11 (55) 59 (53) 
IgD 1 (2) 1 (5) 1 (5) 0 (0) 3 (3) 
Light-chain disease 7 (14) 4 (20) 6 (29) 5 (25) 22 (20) 
Unknown 1 (2) 2 (10) 0 (0) 0 (0) 3 (3) 
Genetic abnormalities, n (%)*     
 
add 1q      
   Yes 5 (10) 4 (20) 2 (10) 7 (35) 18 (16) 
   No 35 (70) 12 (60) 15 (71) 10 (50) 72 (65) 
   Unknown 10 (20) 4 (20) 4 (19) 3 (15) 21 (19) 
t(4;14)(p16;32)       
   Yes 2 (4) 2 (10) 0 (0) 3 (15) 7 (6) 
   No 39 (78) 14 (70) 19 (90) 13 (65) 85 (77) 
   Unknown 9 (18) 4 (20) 2 (10) 4 (20) 19 (17) 
del(17p13)      
   Yes 3 (6) 2 (10) 1 (5) 1 (5) 7 (6) 
   No 38 (76) 14 (70) 18 (86) 16 (80) 86 (77) 
   Unknown 9 (18) 4 (20) 2 (10) 3 (15) 18 (16) 




   Yes 5 (10) 1 (5) 2 (10) 1 (5) 9 (8) 
   No 36 (72) 15 (75) 17 (81) 15 (75) 83 (75) 
   Unknown 9 (18) 4 (20) 2 (10) 4 (20) 19 (17) 
t(14;16)(q32;q23)       
   Yes 3 (6) 1 (5) 0 (0) 0 (0) 4 (4) 
   No 38 (76) 15 (75) 19 (90) 16 (80) 88 (79) 
   Unknown 9 (18) 4 (20) 2 (10) 4 (20) 19 (17) 
Risk status, n (%)†         
  
High 19 (38) 10 (50) 4 (19) 10 (50) 43 (39) 
Standard 21 (42) 6 (30) 12 (57) 7 (35) 46 (41) 
Unknown 10 (20) 4 (20) 5 (24) 3 (15) 22 (20) 
Grade 1/2 PNP, n (%)‡   3 (6) 2 (10) 0 (0) 2 (10) 7 (7) 
 
PNP, polyneuropathy. *A total of 93 patients were evaluable. The table shows the presence of the genetic abnormality in all four dose levels together 
and in each dose level separately. †High-risk: t(4;14) and/or 17p- and/or add1q cytogenetic abnormalities and/or ISS stage 3 disease. Standard risk: 






Table 2: Response after induction, after HDM and after consolidation therapy.  
Dosing level carfilzomib 20/27 mg/m2 20/36 mg/m2 20/45 mg/m2 20/56 mg/m2 All patients 
Patients, n 50 20 21 20 111 
Response after induction, n (%) 
          
  sCR 4 (8) 1 (5) 0 (0) 1 (5) 6 (5) 
  ≥ CR 8 (16) 5 (25) 3 (14) 4 (20) 20 (18) 
  ≥ VGPR 27 (54) 16 (80) 13 (62) 16 (80) 72 (65) 
  ≥ PR 45 (90) 20 (100) 20 (95) 18 (90) 103 (93) 
Response after HDM, n (%) 
          
  sCR 5 (10) 2 (10) 3 (14) 1 (5) 11 (10) 
  ≥ CR 12 (24) 7 (35) 9 (43) 6 (30) 34 (31) 
  ≥ VGPR 32 (64) 17 (85) 19 (90) 18 (90) 86 (77) 
  ≥ PR 46 (92) 20 (100) 20 (95) 18 (90) 104 (94) 
Response after consolidation, n (%) 
          
  sCR 17 (34) 4 (20) 8 (38) 4 (20) 33 (30) 
  ≥ CR 28 (56) 15 (75) 14 (67) 13 (65) 70 (63) 
  ≥ VGPR 40 (80) 18 (90) 20 (95) 18 (90) 96 (86) 
  ≥ PR 46 (92) 20 (100) 20 (95) 18 (90) 104 (94) 











Table 3: Response after consolidation therapy according to risk status and R-ISS 
Standard risk* High-risk* R-ISS 1 R-ISS 2 R-ISS 3 Total 
Patients, n 46 43 26 65 10 111 
  sCR, n (%) 16 (35) 9 (21) 10 (38) 19 (29) 0 (0) 33 (30) 
  ≥ CR, n (%) 31 (67) 25 (58) 19 (73) 37 (57) 6 (60) 70 (63) 
  ≥ VGPR, n (%) 40 (87) 36 (84) 24 (92) 54 (83) 9 (90) 96 (86) 
  ≥ PR, n (%) 44 (96) 38 (88) 26 (100) 58 (91) 10 (100) 104 (94) 
*High-risk: t(4;14) and/or 17p- and/or add1q cytogenetic abnormalities and/or ISS stage 3 disease. Standard risk: the remaining 









Table 4: Cardiac adverse events between dose levels 
  
   20/27 mg/m2, n=50 20/36 mg/m2, n=20   20/45 mg/m2, n=21 20/56 mg/m2, n=20 
Cardiac toxicity, 
n (%) Grade 1/2 Grade 3/4          Grade 1/2    Grade 3/4   Grade 1/2  Grade 3/4 Grade 1/2 Grade 3/4 
Acute coronary 
syndrome 0 (0) 0 (0)   1 (5)   0 (0)  0 (0)        0 (0) 0 (0)       0 (0) 
Atrial flutter 1 (2) 0 (0)   0 (0)   0 (0)  0 (0)        0 (0) 0 (0)       0 (0) 
Atrial fibrillation 1 (2) 0 (0)   0 (0)   0 (0)  0 (0)        0 (0) 0 (0)       0 (0) 
Angina pectoris 3 (6) 0 (0)   1 (5)   0 (0)  2 (10)        1 (5) 1 (5)       0 (0) 
Congestive heart 
failure 1 (2) 2 (4)   1 (5)   0 (0)  0 (0)        0 (0) 0 (0)       1 (5) 
Dyspnea 0 (0) 1 (2)   0 (0)   0 (0)  0 (0)        0 (0) 0 (0)       0 (0) 
Palpitations 1 (2) 0 (0)   1 (5)   0 (0)  1 (5)        0 (0) 0 (0)       0 (0) 
Pericardial fluid 0 (0) 0 (0)   0 (0)   0 (0)  0 (0)        0 (0) 1 (5)       0 (0) 
Total of cardiac 
evens 7 (14) 3 (6)   4 (20)   0 (0)  3 (14)        1 (5) 1 (5)       1 (5) 
 












Normal completion 68 (61) 61 (55) 
Dose delay, reduction and/or interruption 37 (33) 24 (22) 
Premature stop 6 (5) 9 (10) 
Thalidomide 
Normal completion 54 (49) 63 (67) 
Dose delay, reduction and/or interruption 42 (38) 8 (9) 
Premature stop 15 (14) (a) 23 (24) (b) 
Dexamethasone 
Normal completion 85 (77) 66 (70) 
Dose delay, reduction and/or interruption 20 (18) 18 (19) 
Premature stop 6 (5)  10 (11) 
 
(a) Including 9 patients who received no thalidomide during induction cycle 4. (b) Including 14 patients who received no thalidomide 





Figure 1: Consort diagram 
Figure 1: Cyclo, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; HD, high dose; SC, stem cell 
 
Figure 2. Progression-free survival  
Figure 2. Kaplan-Meier curve of progression-free survival (PFS). (A) PFS in all 111 patients. (B) PFS per dose level. (C) PFS 
according to risk status. (D) PFS according to R-ISS.                 
 
Figure 3. Overall survival.  
Figure 3. Kaplan-Meier curve overall survival (OS). (A) OS in all 111 patients. (B) OS per dose level. (C) OS according to risk status. 









Table S1. Treatment-emergent adverse events during therapy.  
 
        Induction therapy 
(N=111) 
       Induction and consolidation therapy 
(N=111) 
Toxicity, n (%) Any grade Grade 3/4 Any grade Grade 3/4 SAE 
Hematologic 7 (6) 5 (5) 17 (15) 11 (10) 3 (3) 
Anemia 5 (5) 4 (4) 9 (8) 4 (4) 0 (0) 
(Febrile) Neutropenia 1 (1) 1 (1) 2 (2) 2 (2) 0 (0) 
Thrombopenia 0 (0) 0 (0) 5 (5) 5 (5) 2 (2) 
Leukopenia 1 (1) 0 (0) 3 (3) 0 (0) 0 (0) 
Other 1 (1) 1 (1) 2 (2) 1 (1) 1 (1) 
Non-hematologic 110 (99) 42 (38) 110 (99) 51 (46) 57 (51) 
General disorders and administration site 
conditions 67 (60) 2 (2) 77 (69) 3 (3) 10 (9) 
Gastrointestinal disorders 59 (53) 3 (3) 64 (58) 3 (3) 6 (5) 
Respiratory, thoracic, and mediastinal 
disorders 37 (33) 7 (6) 51 (46) 9 (8) 4 (4) 
PNP 43 (39) 0 (0) 50 (45) 0 (0) 0 (0) 
Skin and subcutaneous tissue disorders 43 (39) 9 (8) 45 (41) 10 (9) 2 (2) 
Musculature, skeletal, and connective tissue 
disorders 34 (31) 5 (5) 48 (43) 7 (6) 1 (1) 
Vascular disorders 34 (31) 9 (8) 35 (32) 10 (9) 7 (6) 
Cardiac disorders 15 (14) 4 (4) 19 (17) 5 (5) 6 (5) 
Infections and infestations 26 (23) 2 (2) 47 (42) 6 (5) 12 (11) 
Metabolism and nutrition disorders 19 (17) 10 (9) 21 (19) 10 (9) 5 (5) 
Investigations 12 (11) 5 (5) 13 (12) 6 (5) 0 (0) 
Eye disorders 13 (12) 1 (1) 18 (16) 1 (1) 0 (0) 
Psychiatric disorders 8 (7) 0 (0) 12 (11) 0 (0) 0 (0) 
Renal and urinary disorders 9 (8) 3 (3) 12 (11) 3 (3) 2 (2) 
Endocrine disorders 2 (2) 1 (1) 2 (2) 1 (1) 0 (0) 
Surgical and medical procedures 1 (1) 1 (1) 2 (2) 1 (1) 1 (1) 
Immune system disorders 3 (3) 2 (2) 4 (4) 2 (2) 1 (1) 
Table 1. Treatment-emergent adverse events during induction and consolidation therapy, excluding cyclophosphamide and 
HDM. 
  
Table S2. Adherence to treatment protocol during induction and consolidation 
between dose levels. 
 
 
   Induction       
                    
Consolidation       
















Patients (n) 50 20 21 20 41 15 19 19 
Carfilzomib 
        Normal completion 29 (58) 13 (65) 12 (57) 15 (75) 29 (71) 8 (53) 14 (74) 10 (53) 
Dose delay, reduction 
and/or interruption 
17 (34) 6 (30) 9 (43) 4 (20) 11 (27) 6 (40) 3 (16) 4 (21) 
Premature stop 4 (8) 1 (5) - 1 (5) 1 (2) 1 (7) 2 (11) 5 (26) 
Thalidomide 
        
Normal completion 29 (58) 15 (75) 5 (24) 7 (35) 32 (78) 12 (80) 12 (63) 7 (37) 
Dose delay, reduction 
and/or interruption 
15 (30) 4 (20) 14 (67) 10 (50) 3 (7) - 2 (11) 3 (16) 
Premature stop 6 (12) 1 (5) 2 (10) 3 (15) 6 (15) 3 (20) 5 (26) 9 (47) 
Dexamethasone 
    
    
Normal completion 38 (76) 18 (90) 15 (71) 14 (70) 31 (76) 11 (73) 13 (68) 11 (58) 
Dose delay, reduction 
and/or interruption 
8 (16) 1 (5) 6 (29) 5 (25) 8 (20) 3 (20) 4 (21) 3 (16) 
Premature stop 4 (8) 1 (5) - 1 (5) 2 (5) 1 (7) 2 (11) 5 (26) 
